<DOC>
	<DOC>NCT00051493</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.</brief_summary>
	<brief_title>ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>You have a diagnosis of nonsmall cell lung cancer. You have received no prior chemotherapy. You have at least one measurable lesion. You have an adequate performance status. You are at least 18 years of age. You have previously received chemotherapy for your lung cancer. You have received radiation within the last 30 days. You have active infection or other serious condition. You have brain metastasis. You have recently lost a significant amount of weight.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>